Medpace Holdings FY24 EPS $10.18-$10.87 Vs $9.96 Est.; Revenue $2.15B-$2.2B Vs $2.18B Est.
Portfolio Pulse from Benzinga Newsdesk
Medpace Holdings forecasts its FY24 EPS to be between $10.18 and $10.87, surpassing the estimated $9.96. Revenue is expected to be between $2.15B and $2.2B, slightly below the $2.18B estimate. The company anticipates 14.0% to 16.7% revenue growth over 2023, with GAAP net income between $326.0M and $348.0M, and EBITDA between $400.0M and $430.0M. These projections are based on a 16.0% to 17.0% tax rate, $18.4M in interest income, and 32.0M diluted shares, excluding potential share repurchases post-2023.
February 12, 2024 | 9:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medpace Holdings projects higher FY24 EPS of $10.18-$10.87 against a $9.96 estimate, with revenue forecast slightly below expectations at $2.15B-$2.2B. The company expects significant growth and solid financial performance.
The positive EPS forecast exceeding analyst expectations suggests a strong financial outlook for Medpace Holdings, likely leading to a positive short-term impact on its stock price. However, the slightly lower revenue forecast compared to estimates might temper investor enthusiasm, but the overall positive growth projections and solid financial performance indicators such as GAAP net income and EBITDA growth are expected to outweigh the minor revenue shortfall.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100